reproxalap

Small molecule

CRLnot approved

Evidence outlook · regulatory review

Dry Eye Disease: FDA issued a complete response letter (2026-03-16)

FDA issues third complete response letter for reproxalap in dry eye disease. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.

Latest reported trial: NCT06493604 · Phase 3 · met primary endpoint · grade pending

Also in development:Allergic Conjunctivitis · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (11)
Allergic Conjunctivitis
NCT05234554 · Aldeyra Therapeutics, Inc.
2022-01-21 – 2023-04-22 · Allergic Conjunctivitis
What this study did
NCT04207736 · Aldeyra Therapeutics, Inc.
2019-12-05 – 2021-02-16 · Allergic Conjunctivitis
What this study did
Dry Eye Disease
NCT06389214 · Aldeyra Therapeutics, Inc.
2024-04-09 – 2024-06-11 · Dry Eye Disease
What this study did
NCT05062330 · Aldeyra Therapeutics, Inc.
2021-08-28 – 2022-03-04 · Dry Eye
What this study did
Other / comorbidity
NCT03445650 · Aldeyra Therapeutics, Inc.
2018-07-18 – 2020-01-18 · Sjogren-Larsson Syndrome
What this study did
NCT03131154 · Aldeyra Therapeutics, Inc.
2017-04-26 – 2019-04-26 · Non-infectious Anterior Uveitis
What this study did
Phase 2/3 (1)
Dry Eye Disease
NCT04674358 · Aldeyra Therapeutics, Inc.
2020-11-21 – 2021-09-12 · Dry Eye, Dry Eye Syndromes
What this study did
Phase 2 (7)
Allergic Conjunctivitis
NCT03012165 · Aldeyra Therapeutics, Inc.
2016-12 – 2017-05 · Conjunctivitis, Allergic
What this study did
Dry Eye Disease
NCT05424549 · Aldeyra Therapeutics, Inc.
2022-03-09 – 2022-05-09 · Dry Eye Syndromes
What this study did
NCT05102409 · Aldeyra Therapeutics, Inc.
2021-09-09 – 2021-10-25 · Dry Eye
What this study did
NCT04971031 · Aldeyra Therapeutics, Inc.
2021-06-15 – 2021-09-08 · Dry Eye
What this study did
NCT03162783 · Aldeyra Therapeutics, Inc.
2017-05-15 – 2017-07-06 · Dry Eye Syndromes
What this study did
Phase 1/2 (2)
Allergic Conjunctivitis
NCT03660878 · Aldeyra Therapeutics, Inc.
2018-09-08 – 2019-11-19 · Allergic Conjunctivitis
What this study did
NCT03709121 · Aldeyra Therapeutics, Inc.
2018-10-02 – 2019-03-20 · Conjunctivitis, Allergic
What this study did

Competitive landscape

This drug's own stage for Allergic Conjunctivitis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Reproxalap: this drugPhase 3Small moleculeReactive aldehyde species (RASP)Partial signalFeatured results are non-efficacy only in this race
Dexamethasone (Dextenza)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 3Monoclonal antibodyFel d 1 (major cat allergen protein)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 March 2026Complete response letterFDA issues third complete response letter for reproxalap in dry eye disease
US, FDA · Aldeyra Therapeutics · Source ↗
17 July 2025Filing acceptedFDA accepts the resubmitted reproxalap NDA (PDUFA December 16, 2025)
US, FDA · Source ↗
5 May 2025Topline resultDry eye chamber trial (NCT06493604) Phase 3 met its primary endpoint
Aldeyra Therapeutics, Inc. · Source ↗
3 April 2025Complete response letterFDA issues second complete response letter for the resubmitted reproxalap NDA
US, FDA · Aldeyra Therapeutics, Inc. · Source ↗
October 2024Filing submittedReproxalap NDA resubmitted after the 2023 complete response letter
US, FDA · Source ↗
8 August 2024Topline resultDry eye chamber trial (NCT06389214) Phase 3 met its primary endpoint
Aldeyra Therapeutics, Inc. · Source ↗
November 2023Complete response letterFDA issues first complete response letter for reproxalap in dry eye disease
US, FDA · Aldeyra Therapeutics, Inc. · Source ↗
December 2022Filing submittedReproxalap NDA submitted
US, FDA · Source ↗